Published in J Hepatol on April 03, 2010
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J Virol (2011) 1.22
A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility. J Virol (2012) 1.02
Correlation between NS5A dimerization and hepatitis C virus replication. J Biol Chem (2012) 1.01
Peptidyl-prolyl isomerase Pin1 is a cellular factor required for hepatitis C virus propagation. J Virol (2011) 0.98
Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther (2013) 0.98
Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob Agents Chemother (2012) 0.94
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes. Antimicrob Agents Chemother (2012) 0.93
The C terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and release. J Gen Virol (2013) 0.92
Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med (2010) 0.91
Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res (2013) 0.91
Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways. PLoS One (2012) 0.89
Cyclophilins as modulators of viral replication. Viruses (2013) 0.88
HCV NS5A and IRF9 compete for CypA binding. J Hepatol (2012) 0.88
Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. Antimicrob Agents Chemother (2015) 0.88
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses (2010) 0.87
Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. Antimicrob Agents Chemother (2011) 0.87
Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol (2011) 0.86
Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis. J Virol (2012) 0.86
Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes. J Gen Virol (2010) 0.86
HCV core residues critical for infectivity are also involved in core-NS5A complex formation. PLoS One (2014) 0.85
Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol (2014) 0.84
New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. J Zhejiang Univ Sci B (2012) 0.83
Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility. Virology (2013) 0.83
Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals. PLoS One (2011) 0.83
Cyclophilin inhibitors as a novel HCV therapy. Viruses (2010) 0.82
Subtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virus. Viruses (2012) 0.81
Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses (2013) 0.81
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses (2015) 0.81
The role of immunophilins in viral infection. Biochim Biophys Acta (2014) 0.80
An integrated transcriptomic and meta-analysis of hepatoma cells reveals factors that influence susceptibility to HCV infection. PLoS One (2011) 0.80
Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection. Viruses (2012) 0.79
The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action. PLoS One (2015) 0.78
Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma. Korean J Physiol Pharmacol (2013) 0.78
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. World J Gastroenterol (2016) 0.76
Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. Int J Nanomedicine (2015) 0.76
Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells. Open Virol J (2014) 0.75
Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses. PLoS Pathog (2014) 0.75
Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175. PLoS One (2016) 0.75
Infection Counter: Automated Quantification of in Vitro Virus Replication by Fluorescence Microscopy. Viruses (2016) 0.75
Chaperones in hepatitis C virus infection. World J Hepatol (2016) 0.75
Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection. PLoS One (2016) 0.75
Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell (2005) 3.91
Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology (2003) 2.76
Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology (2007) 2.70
Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci (1992) 2.40
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology (2008) 2.24
Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol (2008) 2.22
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. EMBO J (1999) 1.98
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog (2009) 1.94
Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology (2005) 1.85
Therapy of hepatitis C: from empiricism to eradication. Hepatology (2006) 1.80
The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem (2009) 1.79
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology (2009) 1.75
Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol (2006) 1.72
NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother (2006) 1.69
Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J Biol Chem (2009) 1.61
Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol (2003) 1.51
Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol (2009) 1.50
Purification and characterization of hepatitis C virus non-structural protein 5A expressed in Escherichia coli. Protein Expr Purif (2004) 1.45
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother (2009) 1.35
Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun (2006) 1.32
Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol (2006) 1.28
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother (2008) 1.18
Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother (2008) 1.11
Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci (2009) 1.07
Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplant Proc (2005) 1.05
Cyclophilin inhibitors. Clin Liver Dis (2009) 0.94
Effects of cyclosporin A on hepatitis C virus infection in bone marrow transplant patients. Bone Marrow Transplantation Team. Bone Marrow Transplant (1997) 0.93
HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A. Arch Virol (2009) 0.86
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04
Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature (2005) 6.78
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell (2010) 4.47
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J Biol Chem (2005) 2.61
5'-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science (2007) 2.48
Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A (2010) 2.46
Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol (2007) 2.41
Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem (2005) 2.40
Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe (2012) 2.25
Structural determinants that target the hepatitis C virus core protein to lipid droplets. J Biol Chem (2006) 2.18
Nucleic acid polymerases use a general acid for nucleotidyl transfer. Nat Struct Mol Biol (2009) 2.13
Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+. Biochemistry (2004) 2.10
Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol (2005) 2.00
Molecular and biological characterization of deformed wing virus of honeybees (Apis mellifera L.). J Virol (2006) 1.93
Structure-function relationships among RNA-dependent RNA polymerases. Curr Top Microbiol Immunol (2008) 1.90
Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic (2008) 1.89
Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity (2003) 1.86
The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem (2009) 1.79
Poliovirus RNA-dependent RNA polymerase (3Dpol): kinetic, thermodynamic, and structural analysis of ribonucleotide selection. Biochemistry (2004) 1.76
Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A (2009) 1.76
Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol (2006) 1.74
Motif D of viral RNA-dependent RNA polymerases determines efficiency and fidelity of nucleotide addition. Structure (2012) 1.71
The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J Virol (2008) 1.70
Isolation of enzymatically active replication complexes from feline calicivirus-infected cells. J Virol (2002) 1.67
Structure-function relationships of the RNA-dependent RNA polymerase from poliovirus (3Dpol). A surface of the primary oligomerization domain functions in capsid precursor processing and VPg uridylylation. J Biol Chem (2002) 1.61
Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol (2002) 1.61
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem (2010) 1.58
Novel small-molecule inhibitors of RNA polymerase III. Eukaryot Cell (2003) 1.56
Two proton transfers in the transition state for nucleotidyl transfer catalyzed by RNA- and DNA-dependent RNA and DNA polymerases. Proc Natl Acad Sci U S A (2007) 1.55
Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mn2+. Biochemistry (2004) 1.50
A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2008) 1.48
The palm subdomain-based active site is internally permuted in viral RNA-dependent RNA polymerases of an ancient lineage. J Mol Biol (2002) 1.48
Crystal structure of poliovirus 3CD protein: virally encoded protease and precursor to the RNA-dependent RNA polymerase. J Virol (2007) 1.48
Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res (2005) 1.48
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
Purification and characterization of hepatitis C virus non-structural protein 5A expressed in Escherichia coli. Protein Expr Purif (2004) 1.45
Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. J Biol Chem (2005) 1.45
Structural and functional characterization of the coxsackievirus B3 CRE(2C): role of CRE(2C) in negative- and positive-strand RNA synthesis. J Gen Virol (2006) 1.39
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl Trop Dis (2012) 1.36
Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol (2002) 1.34
Core human mitochondrial transcription apparatus is a regulated two-component system in vitro. Proc Natl Acad Sci U S A (2010) 1.34
The herpes simplex virus type 1 DNA packaging protein UL17 is a virion protein that is present in both the capsid and the tegument compartments. J Virol (2005) 1.32
Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J Biol Chem (2006) 1.32
Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J Gen Virol (2006) 1.30
Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol (2009) 1.30
Multiple full-length NS3 molecules are required for optimal unwinding of oligonucleotide DNA in vitro. J Biol Chem (2005) 1.30
Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology (2002) 1.28
Structural and biological identification of residues on the surface of NS3 helicase required for optimal replication of the hepatitis C virus. J Biol Chem (2005) 1.28
Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc Natl Acad Sci U S A (2008) 1.26
A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. J Biol Chem (2005) 1.23
Structure-function relationships of the viral RNA-dependent RNA polymerase: fidelity, replication speed, and initiation mechanism determined by a residue in the ribose-binding pocket. J Biol Chem (2007) 1.23
Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol (2004) 1.23
Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res (2002) 1.22
Molecular dynamics simulations of viral RNA polymerases link conserved and correlated motions of functional elements to fidelity. J Mol Biol (2011) 1.22
Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. Expert Opin Drug Discov (2009) 1.16
Picornavirus genome replication: assembly and organization of the VPg uridylylation ribonucleoprotein (initiation) complex. J Biol Chem (2007) 1.16
Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue. J Virol (2007) 1.16
Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol (2010) 1.15
The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic Acids Res (2009) 1.14
Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog (2012) 1.11
Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole. Biochemistry (2002) 1.11
Transcriptional slippage prompts recoding in alternate reading frames in the hepatitis C virus (HCV) core sequence from strain HCV-1. J Gen Virol (2008) 1.10
Identification of multiple rate-limiting steps during the human mitochondrial transcription cycle in vitro. J Biol Chem (2010) 1.09
Hepatitis C virus (HCV) induces formation of stress granules whose proteins regulate HCV RNA replication and virus assembly and egress. J Virol (2012) 1.08
Proteomic analysis of human immunodeficiency virus using liquid chromatography/tandem mass spectrometry effectively distinguishes specific incorporated host proteins. J Proteome Res (2006) 1.08
Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. J Gen Virol (2010) 1.08
An on-chip, multichannel droplet sorter using standing surface acoustic waves. Anal Chem (2013) 1.08
Challenges for the development of ribonucleoside analogues as inducers of error catastrophe. Antivir Chem Chemother (2004) 1.07
Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob Agents Chemother (2008) 1.07
A Polymerase mechanism-based strategy for viral attenuation and vaccine development. J Biol Chem (2012) 1.06
Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol (2006) 1.05
Norovirus proteinase-polymerase and polymerase are both active forms of RNA-dependent RNA polymerase. J Virol (2005) 1.05
Cyclophilin a plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation. J Virol (2002) 1.05
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother (2007) 1.05
Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res (2012) 1.04
NS3 helicase from the hepatitis C virus can function as a monomer or oligomer depending on enzyme and substrate concentrations. J Biol Chem (2008) 1.04
Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex. J Biol Chem (2004) 1.02
Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Drug Resist Updat (2004) 1.02
Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis. J Virol (2011) 1.01
Correlation between NS5A dimerization and hepatitis C virus replication. J Biol Chem (2012) 1.01
Hepatitis C virus NS3 helicase forms oligomeric structures that exhibit optimal DNA unwinding activity in vitro. J Biol Chem (2008) 1.00
Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol (2008) 0.99
Mobility analysis of an NS5A-GFP fusion protein in cells actively replicating hepatitis C virus subgenomic RNA. J Gen Virol (2007) 0.99